Shenzhen OK Biotech Technology Co., Ltd. (SZOB)
Categories

     Shenzhen OK Biotech Technology Co., Ltd.(SZOB)

     HK Add: 6/F, Fo Tan Industrial Centre, 26-28 Au Pui Wan St ,Fo Tan, Shatin, Hongkong

     China mainland Add: 8F, Fuxuan Building, No. 46, East Heping Rd, Longhua New  District,  Shenzhen, PRC China

     Email: nicole@ok-biotech.com

        smile@ok-biotech.com

     Web: www.ok-biotech.com

     Tel: +852 6679 4580

Home > News > Content

WHO: Tuberculosis Now Rivals AIDS As Leading Cause Of Death

Edit: Shenzhen OK Biotech Technology Co., Ltd. (SZOB)    Date: Oct 29, 2015

www.ok-biotech.com

WHO: Tuberculosis Now Rivals AIDS as Leading Cause of Death

FILE - A doctor points to an X-ray showing a pair of lungs infected with tuberculosis in Ladbroke Grove in London, England, Jan. 27, 2014.

For the first time, tuberculosis infections have rivaled HIV/AIDS as a leading cause of death from infectious diseases, the World Health Organization said in a report released Wednesday.


The report said 1.1 million people died of TB in 2014. During the same period, HIV/AIDS killed 1.2 million people globally, including 400,000 who were infected with both HIV and TB.


Dr. Mario Raviglione, director of the WHO TB program, said the report reflected the dramatic gains in access to HIV/AIDS treatment in the past decade, which has helped many people survive their infections. But it also reflected disparities in funding for the two global killers.


"The good news is that TB intervention has saved some 43 million lives since 2000," but given that most cases of TB can be successfully treated, the death rate remained "unacceptably high," Raviglione said.


The report featured data from 205 countries and territories on all aspects of TB, including drug-resistant forms, research and development, and financing.


It found that 6 million new cases of TB were reported to the WHO in 2014, fewer than two-thirds of the 9.6 million people worldwide estimated to have fallen sick with TB last year.


Among the estimated 480,000 cases of multidrug-resistant TB in 2014 — a superbug form of the disease that resists the two most potent anti-TB drugs — only one in four was diagnosed.


'Wake-up call'


Dr. Grania Brigden, interim medical director of the medical charity Doctors Without Borders, said the report "should serve as a wake-up call that enormous work still needs to be done to reduce the burden of this ancient yet curable disease."


Funding disparities were a key issue, Raviglione said, noting that international funding for HIV/AIDS was 10 times higher than the figure for TB, with $8 million spent on HIV/AIDS interventions compared with $800,000 spent on TB.


Part of that disparity is explained by the fact that HIV/AIDS largely affects resource-poor countries in Africa, whereas TB is more prevalent in countries such as India and China, which are better able to finance their own domestic efforts to address TB infections.


Even so, there remains a $1.4 billion gap in the amount of funding needed for TB interventions in 2015.


Raviglione said it is time to start funding TB at a level that can make even more of a difference in curbing global deaths.


Find more: Flibanserin, CAS 167933-07-5, Testosterone, CAS 58-22-0, Trenbolone acetate, CAS 10161-34-9, Metandienone, CAS 72-63-9, Exemestane, 107868-30-4,

Product Categories
Contact Us
Address: HK: 6/F,Fo Tan Industrial Centre,26-28 Au Pui Wan St,Fo Tan,Shatin,Hongkong Shenzhen: 8F, Fuxuan Building, No. 46, East Heping Rd, Longhua New District, Shenzhen, PRC China
Tel: +852 6679 4580
 Fax:
 E-mail:smile@ok-biotech.com
Shenzhen OK Biotech Technology Co., Ltd.(SZOB)
Share: